Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.2 USD | -0.76% | -7.35% | +10.71% |
09/05 | RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk | MT |
08/05 | Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.71% | 54Cr | |
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.22TCr | |
-3.70% | 2.13TCr | |
-6.03% | 1.9TCr | |
-35.21% | 1.85TCr | |
-10.86% | 1.68TCr | |
+5.10% | 1.39TCr | |
+37.57% | 1.25TCr |
- Stock Market
- Equities
- IGMS Stock
- News IGM Biosciences, Inc.
- Wedbush Cuts IGM Biosciences' PT to $19 From $37, Notes Focus of Aplitabart in mCRC, Removes Potential Imvotamab Oncology Revenues; Keeps Outperform Rating